Literature DB >> 30829341

Generation of Human 3D Lung Tissue Cultures (3D-LTCs) for Disease Modeling.

Michael Gerckens1, Hani N Alsafadi2, Darcy E Wagner2, Michael Lindner3, Gerald Burgstaller4, Melanie Königshoff5.   

Abstract

Translation of novel discoveries to human disease is limited by the availability of human tissue-based models of disease. Precision-cut lung slices (PCLS) used as 3D lung tissue cultures (3D-LTCs) represent an elegant and biologically highly relevant 3D cell culture model, which highly resemble in situ tissue due to their complexity, biomechanics and molecular composition. Tissue slicing is widely applied in various animal models. 3D-LTCs derived from human PCLS can be used to analyze responses to novel drugs, which might further help to better understand the mechanisms and functional effects of drugs in human tissue. The preparation of PCLS from surgically resected lung tissue samples of patients, who experienced lung lobectomy, increases the accessibility of diseased and peritumoral tissue. Here, we describe a detailed protocol for the generation of human PCLS from surgically resected soft-elastic patient lung tissue. Agarose was introduced into the bronchoalveolar space of the resectates, thus preserving lung structure and increasing the tissue's stiffness, which is crucial for subsequent slicing. 500 µm thick slices were prepared from the tissue block with a vibratome. Biopsy punches taken from PCLS ensure comparable tissue sample sizes and further increase the amount of tissue samples. The generated lung tissue cultures can be applied in a variety of studies in human lung biology, including the pathophysiology and mechanisms of different diseases, such as fibrotic processes at its best at (sub-)cellular levels. The highest benefit of the 3D-LTC ex vivo model is its close representation of the in situ human lung in respect of 3D tissue architecture, cell type diversity and lung anatomy as well as the potential for assessment of tissue from individual patients, which is relevant to further develop novel strategies for precision medicine.

Entities:  

Year:  2019        PMID: 30829341     DOI: 10.3791/58437

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  10 in total

1.  Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread.

Authors:  Shubhankar Ambike; Cho-Chin Cheng; Martin Feuerherd; Stoyan Velkov; Domizia Baldassi; Suliman Qadir Afridi; Diana Porras-Gonzalez; Xin Wei; Philipp Hagen; Nikolaus Kneidinger; Mircea Gabriel Stoleriu; Vincent Grass; Gerald Burgstaller; Andreas Pichlmair; Olivia M Merkel; Chunkyu Ko; Thomas Michler
Journal:  Nucleic Acids Res       Date:  2022-01-11       Impact factor: 16.971

Review 2.  Recent Advances in Molecular Diagnosis of Pulmonary Fibrosis for Precision Medicine.

Authors:  Mi Ho Jeong; Hongwei Han; David Lagares; Hyungsoon Im
Journal:  ACS Pharmacol Transl Sci       Date:  2022-07-20

Review 3.  Post-COVID Syndrome: The Research Progress in the Treatment of Pulmonary sequelae after COVID-19 Infection.

Authors:  Valentina Ruggiero; Rita P Aquino; Pasquale Del Gaudio; Pietro Campiglia; Paola Russo
Journal:  Pharmaceutics       Date:  2022-05-26       Impact factor: 6.525

Review 4.  Precision-cut lung slices: A powerful ex vivo model to investigate respiratory infectious diseases.

Authors:  Flávia Viana; Cecilia M O'Kane; Gunnar N Schroeder
Journal:  Mol Microbiol       Date:  2021-10-31       Impact factor: 3.979

Review 5.  Implementation of pre-clinical methodologies to study fibrosis and test anti-fibrotic therapy.

Authors:  Fiona Oakley; Lucy M Gee; Neil S Sheerin; Lee A Borthwick
Journal:  Curr Opin Pharmacol       Date:  2019-11-12       Impact factor: 5.547

6.  An integrated multiomic and quantitative label-free microscopy-based approach to study pro-fibrotic signalling in ex vivo human precision-cut lung slices.

Authors:  Muzamil Majid Khan; Daniel Poeckel; Aliaksandr Halavatyi; Joanna Zukowska-Kasprzyk; Frank Stein; Johanna Vappiani; Daniel C Sevin; Christian Tischer; Nico Zinn; Jessica D Eley; Natasja Stæhr Gudmann; Thomas Muley; Hauke Winter; Andrew J Fisher; Carmel B Nanthakumar; Giovanna Bergamini; Rainer Pepperkok
Journal:  Eur Respir J       Date:  2021-07-01       Impact factor: 16.671

7.  Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes.

Authors:  Domizia Baldassi; Shubhankar Ambike; Martin Feuerherd; Cho-Chin Cheng; David J Peeler; Daniel P Feldmann; Diana Leidy Porras-Gonzalez; Xin Wei; Lea-Adriana Keller; Nikolaus Kneidinger; Mircea Gabriel Stoleriu; Andreas Popp; Gerald Burgstaller; Suzie H Pun; Thomas Michler; Olivia M Merkel
Journal:  J Control Release       Date:  2022-03-29       Impact factor: 11.467

8.  The Challenge of Long-Term Cultivation of Human Precision-Cut Lung Slices.

Authors:  Eike B Preuß; Stephanie Schubert; Christopher Werlein; Helge Stark; Peter Braubach; Anne Höfer; Edith K J Plucinski; Harshit R Shah; Robert Geffers; Katherina Sewald; Armin Braun; Danny D Jonigk; Mark P Kühnel
Journal:  Am J Pathol       Date:  2021-11-10       Impact factor: 4.307

9.  Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics.

Authors:  Michael Gerckens; Kenji Schorpp; Francesco Pelizza; Melanie Wögrath; Kora Reichau; Huilong Ma; Armando-Marco Dworsky; Arunima Sengupta; Mircea Gabriel Stoleriu; Katharina Heinzelmann; Juliane Merl-Pham; Martin Irmler; Hani N Alsafadi; Eduard Trenkenschuh; Lenka Sarnova; Marketa Jirouskova; Wolfgang Frieß; Stefanie M Hauck; Johannes Beckers; Nikolaus Kneidinger; Jürgen Behr; Anne Hilgendorff; Kamyar Hadian; Michael Lindner; Melanie Königshoff; Oliver Eickelberg; Martin Gregor; Oliver Plettenburg; Ali Önder Yildirim; Gerald Burgstaller
Journal:  Sci Adv       Date:  2021-12-22       Impact factor: 14.957

10.  Functional changes in long-term incubated rat precision-cut lung slices.

Authors:  Aaron Babendreyer; Christian Martin; Sarah Marie Nußbaum; Julia Krabbe; Svenja Böll
Journal:  Respir Res       Date:  2022-09-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.